Brent Saunders, one of biopharma’s most prominent dealmakers and highest-paid leaders, is out as CEO of Bausch + Lomb, failing to add another multibillion-dollar company sale …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.